Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

Intercell AG: Announcement according to section 93 subsection 1 and 2 of the Austrian Stock Markets Act

Wien (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
shares
Vienna (Austria), September 28, 2007 - Following
the completion of a capital increase of 4.8 million shares, which 
were sold to Novartis Pharma AG at an issue price of EUR 31.25 per 
share, or EUR 150 million in total, and admission of the new shares 
for trading on the Official Market of the Vienna Stock Exchange, 
Intercell AG, with its principal offices in Vienna, makes the 
following required announcement about changes in the allocation of 
voting rights:
Announcement of Novartis´ share in voting rights according to section
93 subsection 2 of the Austrian Stock Exchange Act:
Novartis AG has informed us that entities affiliated with Novartis AG
now hold 7,244,940 shares, representing 15.9 percent of the voting 
rights in Intercell AG, subdivided into 4,800,000 shares (10.5%) for 
Novartis Pharma AG, 2,400,000 shares (5.3%) for Novartis Vaccines and
Diagnostics, Inc. and 44,940 shares (0.1%) for Novartis Vaccines and 
Diagnostics GmbH & Co. KG.
Announcement of the total number of voting rights according to 
section 93 subsection 1 of the Austrian Stock Markets Act:
The total number of shares of common stock with no par value of 
Intercell AG, each representing one vote, has increased to 
45,521,707. The share capital is now EUR 45,521,707.-.
The Management Board
end of announcement                               euro adhoc 28.09.2007 07:25:54

Further inquiry note:

Intercell AG
Mag. Dott. Astrid Meinl
Corporate Communications Manager
Tel. +43 1 20620-313
ameinl@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG